Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India
暂无分享,去创建一个
S. Menon | K. Prabhash | V. Noronha | A. Ramaswamy | V. Patil | N. Sable | P. Popat | A. Sahu | A. Joshi | R. Kothari | R. Kannan
[1] A. Sella,et al. The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials. , 2016, Clinical genitourinary cancer.
[2] P. Shao,et al. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma , 2016, Scientific Reports.
[3] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[4] L. Pickering,et al. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Kumaraswamy,et al. Concurrent Chemoradiation for Cancer of the Cervix: Results of a Multi-Institutional Study From the Setting of a Developing Country (India) , 2015, Journal of global oncology.
[6] C. Porta,et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.
[7] M. Fishman,et al. A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting , 2015, PloS one.
[8] T. Choueiri,et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.
[9] R. Kapoor,et al. Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation , 2014, The Indian journal of medical research.
[10] Kenya Yamaguchi,et al. Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC. , 2014 .
[11] G. Hermann,et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. , 2014, European journal of cancer.
[12] Kumar Gaurav,et al. Emerging risk factors for cardiovascular diseases: Indian context , 2013, Indian journal of endocrinology and metabolism.
[13] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[14] K. Prabhash,et al. Sunitinib in metastatic renal cell carcimoma: a single-center experience. , 2013, Indian journal of cancer.
[15] U. Harmenberg,et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008) , 2013, British Journal of Cancer.
[16] T. Choueiri,et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.
[17] P. Lara,et al. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. , 2012, Clinical genitourinary cancer.
[18] Choung-Soo Kim,et al. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features , 2012, Journal of Cancer Research and Clinical Oncology.
[19] C. Bokemeyer,et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] J. Hajdenberg,et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.
[21] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[23] D. Cella,et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[25] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] D. Pal,et al. Clinical characteristics of renal cell carcinoma: Five years review from a tertiary hospital in Eastern India. , 2016, Indian journal of cancer.
[27] T. Choueiri,et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] M. Gordon. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .